GB9404485D0
(en)
*
|
1994-03-09 |
1994-04-20 |
Cancer Res Campaign Tech |
Benzamide analogues
|
US5589483A
(en)
*
|
1994-12-21 |
1996-12-31 |
Geron Corporation |
Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
|
RU2106864C1
(ru)
*
|
1995-10-23 |
1998-03-20 |
Николай Серафимович Зефиров |
Средство для лечения болезни альцгеймера
|
AU8784698A
(en)
*
|
1997-08-15 |
1999-03-08 |
Johns Hopkins University, The |
Method of using selective parp inhibitors to prevent or treat neurotoxicity
|
US6358975B1
(en)
|
1997-08-15 |
2002-03-19 |
Johns Hopkins University |
Method of using selective parp inhibitors to prevent or treat neurotoxicity
|
US6440455B1
(en)
*
|
1997-09-02 |
2002-08-27 |
Children's Medical Center Corporation |
Methods for modulating the axonal outgrowth of central nervous system neurons
|
US6346536B1
(en)
|
1997-09-03 |
2002-02-12 |
Guilford Pharmaceuticals Inc. |
Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same
|
US6291425B1
(en)
|
1999-09-01 |
2001-09-18 |
Guilford Pharmaceuticals Inc. |
Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
|
US6197785B1
(en)
|
1997-09-03 |
2001-03-06 |
Guilford Pharmaceuticals Inc. |
Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
|
US6514983B1
(en)
|
1997-09-03 |
2003-02-04 |
Guilford Pharmaceuticals Inc. |
Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
|
US6235748B1
(en)
|
1997-09-03 |
2001-05-22 |
Guilford Pharmaceuticals Inc. |
Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
|
US6426415B1
(en)
|
1997-09-03 |
2002-07-30 |
Guilford Pharmaceuticals Inc. |
Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
|
US6635642B1
(en)
|
1997-09-03 |
2003-10-21 |
Guilford Pharmaceuticals Inc. |
PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
|
US6333148B1
(en)
|
1998-05-01 |
2001-12-25 |
University Of Kentucky Research |
Genes encoding several poly (ADP-ribose) glycohydrolase (PARG) enzymes, the proteins and fragments thereof, and antibodies immunoreactive therewith
|
EP1077944A1
(en)
*
|
1998-05-15 |
2001-02-28 |
Guilford Pharmaceuticals Inc. |
Carboxamide compounds, compositions, and methods for inhibiting parp activity
|
US6395749B1
(en)
|
1998-05-15 |
2002-05-28 |
Guilford Pharmaceuticals Inc. |
Carboxamide compounds, methods, and compositions for inhibiting PARP activity
|
US20030078212A1
(en)
*
|
1998-10-30 |
2003-04-24 |
Jia-He Li |
Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same
|
US6201020B1
(en)
|
1998-12-31 |
2001-03-13 |
Guilford Pharmaceuticals, Inc. |
Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
|
US6387902B1
(en)
|
1998-12-31 |
2002-05-14 |
Guilford Pharmaceuticals, Inc. |
Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
|
EE05006B1
(et)
|
1999-01-11 |
2008-04-15 |
Agouron Pharmaceuticals, Inc. |
Polü(ADP-riboos)polümeraaside tritsüklilised inhibiitorid ja neid sisaldavad farmatseutilised kompositsioonid
|
US6187822B1
(en)
*
|
1999-06-11 |
2001-02-13 |
University Of Medicine & Dentistry Of Nj |
Wound treatment through inhibition of adenosine diphosphate ribosyl transferase
|
ECSP003637A
(es)
|
1999-08-31 |
2002-03-25 |
Agouron Pharma |
Inhibidores triciclicos de poli (adp-ribosa) polimerasas
|
US6531464B1
(en)
*
|
1999-12-07 |
2003-03-11 |
Inotek Pharmaceutical Corporation |
Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
|
US6277990B1
(en)
|
1999-12-07 |
2001-08-21 |
Inotek Corporation |
Substituted phenanthridinones and methods of use thereof
|
US6476048B1
(en)
|
1999-12-07 |
2002-11-05 |
Inotek Pharamaceuticals Corporation |
Substituted phenanthridinones and methods of use thereof
|
US6444676B1
(en)
|
1999-12-20 |
2002-09-03 |
Iok-Hou Pang |
Use of PARP inhibitors in the treatment of glaucoma
|
US7122679B2
(en)
|
2000-05-09 |
2006-10-17 |
Cephalon, Inc. |
Multicyclic compounds and the use thereof
|
US20060276497A1
(en)
*
|
2000-05-09 |
2006-12-07 |
Cephalon, Inc. |
Novel multicyclic compounds and the use thereof
|
AU2001264595A1
(en)
|
2000-05-19 |
2001-12-03 |
Guilford Pharmaceuticals Inc. |
Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
|
US6348475B1
(en)
*
|
2000-06-01 |
2002-02-19 |
Guilford Pharmaceuticals Inc. |
Methods, compounds and compositions for treating gout
|
AU2001273099A1
(en)
|
2000-07-13 |
2002-01-30 |
Guilford Pharmaceuticals Inc. |
Substituted 4,9-dihydrocyclopenta(imn) phenanthridine-5-ones, derivatives thereof and their uses
|
US7151102B2
(en)
*
|
2000-10-30 |
2006-12-19 |
Kudos Pharmaceuticals Limited |
Phthalazinone derivatives
|
MXPA03006372A
(es)
*
|
2001-01-16 |
2004-04-20 |
Guilford Pharm Inc |
Compuestos aromaticos simetricamente disustituidos y composiciones farmaceuticas para inhibir poli (adp-ribosa) glicohidrolasa y metodos para su uso.
|
WO2002072542A2
(en)
*
|
2001-03-08 |
2002-09-19 |
Emory University |
Ph-dependent nmda receptor antagonists
|
US20020177614A1
(en)
*
|
2001-03-23 |
2002-11-28 |
Merril Carl R. |
Methods for treating nuerodegenerative diseases including alzheimer's
|
US7072771B2
(en)
*
|
2001-06-07 |
2006-07-04 |
University Of Kentucky Research Foundation |
Selective PARP-1 targeting for designing chemo/radio sensitizing agents
|
KR100957516B1
(ko)
*
|
2001-08-15 |
2010-05-14 |
이코스 코포레이션 |
2h-프탈라진-1-온 및 이것의 사용 방법
|
DE60335359D1
(de)
*
|
2002-04-30 |
2011-01-27 |
Kudos Pharm Ltd |
Phthalazinonderivate
|
GB0305681D0
(en)
|
2003-03-12 |
2003-04-16 |
Kudos Pharm Ltd |
Phthalazinone derivatives
|
US7449464B2
(en)
*
|
2003-03-12 |
2008-11-11 |
Kudos Pharmaceuticals Limited |
Phthalazinone derivatives
|
JP2006522088A
(ja)
*
|
2003-03-31 |
2006-09-28 |
ファイザー・インク |
ポリ(adp−リボース)ポリメラーゼの三環系阻害剤の塩
|
US20080161255A1
(en)
*
|
2003-05-29 |
2008-07-03 |
Michael Brownlee |
Use of Parp Inhibitors for Prevention and Treatment of Diabetic and Insulin Resistance Complications
|
PL1684736T3
(pl)
|
2003-12-01 |
2012-01-31 |
Kudos Pharm Ltd |
Inhibitory naprawy DNA w leczeniu raka
|
US20070179174A1
(en)
*
|
2003-12-08 |
2007-08-02 |
Bachurin Sergei O |
Methods and compositions for slowing aging
|
RU2283108C2
(ru)
*
|
2003-12-08 |
2006-09-10 |
Сергей Олегович Бачурин |
ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
|
US8912144B2
(en)
*
|
2003-12-16 |
2014-12-16 |
Children's Medical Center Corporation |
Method for treating stroke via administration of NEP1-40 and inosine
|
EP1758566A2
(en)
*
|
2004-06-22 |
2007-03-07 |
Pharmos Limited |
Use of cb2 receptors agonists for the treatment of huntington"s disease
|
GB0419072D0
(en)
*
|
2004-08-26 |
2004-09-29 |
Kudos Pharm Ltd |
Phthalazinone derivatives
|
GB0428111D0
(en)
*
|
2004-12-22 |
2005-01-26 |
Kudos Pharm Ltd |
Pthalazinone derivatives
|
CN101223175B
(zh)
|
2005-01-19 |
2013-03-27 |
卫材有限公司 |
二氮杂苯并[de]蒽-3-酮化合物及抑制PARP的方法
|
US20070117835A1
(en)
*
|
2005-10-04 |
2007-05-24 |
David Hung |
Methods and compositions for treating Huntington's disease
|
GB0521373D0
(en)
|
2005-10-20 |
2005-11-30 |
Kudos Pharm Ltd |
Pthalazinone derivatives
|
JP2009539962A
(ja)
*
|
2006-06-15 |
2009-11-19 |
クドス ファーマシューティカルズ リミテッド |
Parp阻害剤としての2−オキシヘテロアリールアミド誘導体
|
EP2041087A1
(en)
*
|
2006-06-15 |
2009-04-01 |
Kudos Pharmaceuticals Limited |
2 -oxybenzamide derivatives as parp inhibitors
|
WO2007144652A2
(en)
*
|
2006-06-15 |
2007-12-21 |
Kudos Pharmaceuticals Limited |
Parp inhibitors
|
UY30639A1
(es)
*
|
2006-10-17 |
2008-05-31 |
Kudos Pharm Ltd |
Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
|
US20080280910A1
(en)
*
|
2007-03-22 |
2008-11-13 |
Keith Allan Menear |
Phthalazinone derivatives
|
TW200900396A
(en)
*
|
2007-04-10 |
2009-01-01 |
Kudos Pharm Ltd |
Phthalazinone derivatives
|
BRPI0813001A2
(pt)
|
2007-06-29 |
2019-09-24 |
Univ Emory |
composto, método de tratamento ou profilaxia de dor neuropática e composição farmacêutica
|
US20090023727A1
(en)
*
|
2007-07-05 |
2009-01-22 |
Muhammad Hashim Javaid |
Phthalazinone derivatives
|
CN101809017A
(zh)
|
2007-09-14 |
2010-08-18 |
阿斯利康(瑞典)有限公司 |
酞嗪酮衍生物
|
AU2008313467B2
(en)
*
|
2007-10-17 |
2013-08-29 |
Kudos Pharmaceuticals Limited |
4- [3- (4-cyclopropanecarbonyl-piperazine-1-carbonyl) -4 -fluoro-benzyl] -2H-phthalazin-1-one
|
UY31603A1
(es)
|
2008-01-23 |
2009-08-31 |
|
Derivados de ftalazinona
|
EP2346495B2
(en)
*
|
2008-10-07 |
2023-05-24 |
Kudos Pharmaceuticals Limited |
Pharmaceutical formulation 514
|
US20110015393A1
(en)
*
|
2009-07-15 |
2011-01-20 |
Astrazeneca Ab |
Phthalazinone compound
|
WO2011058367A2
(en)
|
2009-11-13 |
2011-05-19 |
Astrazeneca Ab |
Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
|
EP2609216B1
(en)
|
2010-08-24 |
2016-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods for predicting anti-cancer response
|
ES2768344T3
(es)
|
2011-06-17 |
2020-06-22 |
Myriad Genetics Inc |
Métodos y materiales para evaluar el desequilibrio alélico
|
US10378060B2
(en)
|
2011-10-14 |
2019-08-13 |
Dana-Farber Cancer Institute, Inc. |
ZNF365/ZFP365 biomarker predictive of anti-cancer response
|
JP6325453B2
(ja)
|
2011-12-21 |
2018-05-16 |
ミリアド・ジェネティックス・インコーポレイテッド |
ヘテロ接合性の消失(lossofheterozygosity)を評価するための方法および材料
|
ES2687024T3
(es)
|
2012-02-23 |
2018-10-23 |
Children's Medical Center Corporation |
Procedimientos para predecir la respuesta contra el cáncer
|
WO2013182645A1
(en)
|
2012-06-07 |
2013-12-12 |
Institut Curie |
Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
|
US10308986B2
(en)
|
2013-03-14 |
2019-06-04 |
Children's Medical Center Corporation |
Cancer diagnosis, treatment selection and treatment
|
US11149316B2
(en)
|
2013-12-09 |
2021-10-19 |
Institut Curie |
Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors
|
RU2682335C2
(ru)
|
2014-01-17 |
2019-03-19 |
Сидарс-Синай Медикал Сентр |
Рецептор-направленные конструкции и их применение
|
CA2944903A1
(en)
|
2014-04-24 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
|
ES2800673T3
(es)
|
2014-08-15 |
2021-01-04 |
Myriad Genetics Inc |
Métodos y materiales para evaluar una deficiencia de recombinación homóloga
|
JP7095990B2
(ja)
|
2014-09-18 |
2022-07-05 |
シーダーズ-サイナイ メディカル センター |
線維症を治療するための組成物及び方法
|
WO2016057367A1
(en)
|
2014-10-06 |
2016-04-14 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
CN107106669A
(zh)
|
2014-11-04 |
2017-08-29 |
南加利福尼亚大学 |
用于治疗过度表达HIF‑1α的癌症的组合物和方法
|
AU2015360903B2
(en)
|
2014-12-08 |
2021-03-25 |
Dana-Farber Cancer Institute, Inc. |
Methods for upregulating immune responses using combinations of anti-RGMB and anti-PD-1 agents
|
JP6871169B2
(ja)
|
2015-03-02 |
2021-05-12 |
シナイ ヘルス システム |
相同組換え因子
|
US10948492B2
(en)
|
2015-03-06 |
2021-03-16 |
Dana-Farber Cancer Institute, Inc. |
PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers
|
CN108138177B9
(zh)
|
2015-07-23 |
2021-08-13 |
法国居里学院 |
Dbait分子与PARP抑制剂的组合用于治疗癌症的用途
|
EP3362074B1
(en)
|
2015-10-16 |
2023-08-09 |
President and Fellows of Harvard College |
Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
|
GB201519573D0
(en)
|
2015-11-05 |
2015-12-23 |
King S College London |
Combination
|
US11136409B2
(en)
|
2016-09-20 |
2021-10-05 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators
|
WO2018162439A1
(en)
|
2017-03-08 |
2018-09-13 |
Onxeo |
New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
|
AU2018260094A1
(en)
|
2017-04-28 |
2019-11-07 |
Akribes Biomedical Gmbh |
A PARP inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
|
KR20200130856A
(ko)
|
2018-03-13 |
2020-11-20 |
옹쎄오 |
암 치료에서 획득한 내성에 대한 디베이트 분자
|
EP3833762A4
(en)
|
2018-08-09 |
2022-09-28 |
Verseau Therapeutics, Inc. |
OLIGONUCLEOTIDE COMPOSITIONS FOR TARGETING CCR2 AND CSF1R AND THEIR USES
|
WO2020223121A1
(en)
|
2019-04-30 |
2020-11-05 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
|
GB201913030D0
(en)
|
2019-09-10 |
2019-10-23 |
Francis Crick Institute Ltd |
Treatment of hr deficient cancer
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
WO2022086852A2
(en)
|
2020-10-19 |
2022-04-28 |
Dana-Farber Cancer Institute, Inc. |
Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
|
US20240024474A1
(en)
|
2020-11-13 |
2024-01-25 |
David Avigan |
Personalized fusion cell vaccines
|
EP4281187A1
(en)
|
2021-01-20 |
2023-11-29 |
Bioentre LLC |
Ctla4-binding proteins and methods of treating cancer
|
US20240158864A1
(en)
|
2021-01-25 |
2024-05-16 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for identifying neuroendocrine prostate cancer
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
WO2023043888A1
(en)
|
2021-09-15 |
2023-03-23 |
Celloram Inc. |
Method of treating cancer
|
WO2023240287A1
(en)
|
2022-06-10 |
2023-12-14 |
Bioentre Llc |
Combinations of ctla4 binding proteins and methods of treating cancer
|